Progresses in medicinal chemistry over the last few years have focused on the design and synthesis of hybrid compounds, molecules encompassing in a single scaffold two pharmacophores from known entities endowed with well established biological activities. The interest in this topic is related to the increasing emphasis on the identification of the different factors involved in a number of disorders, such as the complex multifactorial Alzheimer’s disease (AD), and hybrid-based strategy has become a focal point in this medicinal chemistry field since it could lead to derivatives with an improved biological profile. Using this strategy, acetylcholinesterase inhibitors (AChEIs) have been extensively coupled with properly selected bioactive molecules to obtain homo- and heterodimers endowed with increased potency together with supplementary actions. In the past decade the inhibition of the AChE induced aggregation of the beta-amyloid peptide into the senile plaques, which is a key event in the neurotoxic cascade of AD, has been%2
A. Rampa, F. Belluti, S. Gobbi, A. Bisi (2011). Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 11, 2716-2730 [10.2174/156802611798184409].
Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
RAMPA, ANGELA;BELLUTI, FEDERICA;GOBBI, SILVIA;BISI, ALESSANDRA
2011
Abstract
Progresses in medicinal chemistry over the last few years have focused on the design and synthesis of hybrid compounds, molecules encompassing in a single scaffold two pharmacophores from known entities endowed with well established biological activities. The interest in this topic is related to the increasing emphasis on the identification of the different factors involved in a number of disorders, such as the complex multifactorial Alzheimer’s disease (AD), and hybrid-based strategy has become a focal point in this medicinal chemistry field since it could lead to derivatives with an improved biological profile. Using this strategy, acetylcholinesterase inhibitors (AChEIs) have been extensively coupled with properly selected bioactive molecules to obtain homo- and heterodimers endowed with increased potency together with supplementary actions. In the past decade the inhibition of the AChE induced aggregation of the beta-amyloid peptide into the senile plaques, which is a key event in the neurotoxic cascade of AD, has been%2I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.